Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y Zacks Equity Research - Zacks Investment Research - Wed May 23, 2:05PM CDT Zacks Equity Research - ZACKS - Wed May 23, 2:05PM CDT
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
Dr. Reddy's to Release Q4 and Full Year FY18 Results on May 22, 2018 BusinessWire - Wed Apr 25, 2:51AM CDT CMTX - Wed Apr 25, 2:51AM CDT
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will
announce results for the Fourth Quarter and Full year ended March 31,
2018 on Tuesday, May 22, 2018 after the Board Meeting....
BioSim Pharmaceuticals Selects CPC Scientific as Key Supplier in the Manufacture of BioSim's ACTH Gel BusinessWire - Tue Apr 24, 9:05AM CDT CMTX - Tue Apr 24, 9:05AM CDT
BioSim Pharmaceuticals, Inc. today announced that it has selected CPC
Scientific to supply BioSim with their cGMP ACTH peptide. BioSim's ACTH
Gelatin Depot 80 IU/mL product is a copy of the...
Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate BusinessWire - Mon Apr 2, 3:19AM CDT CMTX - Mon Apr 2, 3:19AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and
its subsidiary, Promius Pharma, LLC today announced the filing of New
Drug Application (NDA) for its migraine candidate...
BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod Zacks Equity Research - Zacks Investment Research - Thu Mar 29, 8:54AM CDT Zacks Equity Research - ZACKS - Thu Mar 29, 8:54AM CDT
BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.
Dr. Reddy's Laboratories Announces Senior Leadership Changes BusinessWire - Thu Mar 29, 12:45AM CDT CMTX - Thu Mar 29, 12:45AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
today announced a change in the makeup of its senior leadership team.
Dr. Reddy's Laboratories Announces the Launch of Palonosetron Hydrochloride Injection in the U.S. Market BusinessWire - Mon Mar 26, 12:34AM CDT CMTX - Mon Mar 26, 12:34AM CDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
announced today that it has launched Palonosetron Hydrochloride
Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent...
Blog Exposure - Dr. Reddy's Launches its Levocetirizine Dihydrochloride Tablets in the US Market ACCESSWIRE - Tue Mar 20, 6:50AM CDT CMTX - Tue Mar 20, 6:50AM CDT
Stock Monitor: Amphastar Pharma Post Earnings Reporting
Dr. Reddy's Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market BusinessWire - Fri Mar 16, 2:42AM CDT CMTX - Fri Mar 16, 2:42AM CDT
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
announced today that it has launched Levocetirizine Dihydrochloride
Tablets USP, 5 mg, an over-the-counter therapeutic...
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals Zacks Equity Research - Zacks Investment Research - Mon Mar 12, 8:08AM CDT Zacks Equity Research - ZACKS - Mon Mar 12, 8:08AM CDT
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Pharma Stocks Weighed Down by Competition, Generic Pressure Zacks Equity Research - Zacks Investment Research - Fri Mar 9, 1:18PM CST Zacks Equity Research - ZACKS - Fri Mar 9, 1:18PM CST
Pharma Stocks Weighed Down by Competition, Generic Pressure
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against NQ Mobile Inc. (NQ) & Lead Plaintiff Deadline: April 11, 2018 PR Newswire - Wed Feb 21, 9:10AM CST PRNW - Wed Feb 21, 9:10AM CST
NEW YORK , Feb. 21, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NQ Mobile Inc. ("NQ Mobile"...
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised) Zacks Equity Research - Zacks Investment Research - Fri Feb 16, 3:23AM CST Zacks Equity Research - ZACKS - Fri Feb 16, 3:23AM CST
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment Zacks Equity Research - Zacks Investment Research - Thu Feb 15, 8:19AM CST Zacks Equity Research - ZACKS - Thu Feb 15, 8:19AM CST
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Generic Drugmakers to Dump as Teva's Woes Continue in 2018 Zacks Equity Research - Zacks Investment Research - Tue Feb 13, 5:02PM CST Zacks Equity Research - ZACKS - Tue Feb 13, 5:02PM CST
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y Zacks Equity Research - Zacks Investment Research - Thu Jan 25, 9:30AM CST Zacks Equity Research - ZACKS - Thu Jan 25, 9:30AM CST
Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
Dr. Reddy's Laboratories Limited to Present at the 36th Annual J.P. Morgan Healthcare Conference BusinessWire - Sat Jan 6, 12:39AM CST CMTX - Sat Jan 6, 12:39AM CST
Dr. Reddy's Laboratories Ltd (BSE: 500124)(NSE: DRREDDY)(NYSE: RDY)
announced that the Company will be presenting at the 36th Annual J.P.
Morgan Healthcare Conference in San Francisco, California....
Dr. Reddy's Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market BusinessWire - Tue Dec 26, 3:37AM CST CMTX - Tue Dec 26, 3:37AM CST
Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
announced today that it has launched Melphalan Hydrochloride for
Injection, a therapeutic equivalent generic version of...
Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the Consumer Product Safety Act BusinessWire - Mon Dec 18, 11:38PM CST CMTX - Mon Dec 18, 11:38PM CST
(BSE: 500124, NSE: DRREDDY, NYSE: RDY)--The US subsidiary of Dr. Reddy's
Laboratories Ltd. announced today that it has reached a settlement with
the US Government, in a case that is more...
Dr. Reddy's Announces Approval of Impoyz(TM) (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval BusinessWire - Fri Dec 1, 12:05AM CST CMTX - Fri Dec 1, 12:05AM CST
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY),
through its wholly owned subsidiary Promius Pharma, LLC, today announced
its fifth consecutive, first-cycle NDA approval...
